| __timestamp | Incyte Corporation | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 1860000 |
| Thursday, January 1, 2015 | 196614000 | 2963000 |
| Friday, January 1, 2016 | 303251000 | 6961000 |
| Sunday, January 1, 2017 | 366406000 | 11779000 |
| Monday, January 1, 2018 | 434407000 | 13697000 |
| Tuesday, January 1, 2019 | 468711000 | 15749000 |
| Wednesday, January 1, 2020 | 516922000 | 18638000 |
| Friday, January 1, 2021 | 739560000 | 27196000 |
| Saturday, January 1, 2022 | 1002140000 | 31739000 |
| Sunday, January 1, 2023 | 1161300000 | 33491000 |
| Monday, January 1, 2024 | 1242157000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Incyte Corporation and Protagonist Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Incyte's SG&A expenses surged by over 600%, reflecting its aggressive expansion and market penetration strategies. In contrast, Protagonist Therapeutics maintained a more conservative growth, with SG&A costs increasing by approximately 1,700% but from a much smaller base, indicating a more cautious approach to scaling operations.
Incyte's expenses peaked in 2023, reaching nearly 1.2 billion, while Protagonist's expenses were a modest 33 million. This disparity highlights Incyte's larger operational scale and market presence. For investors and industry watchers, these trends underscore the importance of strategic cost management in achieving sustainable growth in the biotech sector.
SG&A Efficiency Analysis: Comparing Novartis AG and Incyte Corporation
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Incyte Corporation
Who Optimizes SG&A Costs Better? GSK plc or Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing argenx SE and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Incyte Corporation
BeiGene, Ltd. or Incyte Corporation: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Incyte Corporation and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Incyte Corporation and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Corcept Therapeutics Incorporated
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.